Prolor Biotech (NASDAQ: PBTH) was downgraded by research analysts at Summer Street from a “buy” rating to a “sell” rating in a report released on Monday.
Prolor Biotech traded down 3.16% on Monday, hitting $4.60. Prolor Biotech has a 52-week low of $3.11 and a 52-week high of $6.69. The company’s market cap is $291.7 million.
Several other analysts have also recently commented on the stock. Analysts at Oppenheimer initiated coverage on shares of Prolor Biotech in a research note to investors on Wednesday, August 29th. They set an “outperform” rating and a $7.00 price target on the stock. Analysts at Jefferies Group initiated coverage on shares of Prolor Biotech in a research note to investors on Wednesday, August 22nd. They set a “buy” rating and a $8.00 price target on the stock.
Prolor Biotech, Inc. (Prolor), formerly Modigene Inc. is a development-stage biopharmaceutical company, utilizing technology to develop versions of therapeutic proteins.